Neurogenic responses mediated by vanilloid receptor-1 (TRPV1) are blocked by the high affinity antagonist, iodo-resiniferatoxin by Rigoni, Michela et al.
Neurogenic responses mediated by 
vanilloid receptor­1 (TRPV1) are blocked 
by the high affinity antagonist, iodo­
resiniferatoxin 
Article 
Published Version 
OnlineOpen 
Rigoni, M., Trevisani, M., Gazzieri, D., Nadaletto, R., 
Tognetto, M., Creminon, C., Davis, J. B., Campi, B., Amadesi, 
S., Geppetti, P. and Harrison, S. (2003) Neurogenic responses 
mediated by vanilloid receptor­1 (TRPV1) are blocked by the 
high affinity antagonist, iodo­resiniferatoxin. British Journal of 
Pharmacology, 138 (5). pp. 977­985. ISSN 0007­1188 
Available at http://centaur.reading.ac.uk/35818/ 
It is advisable to refer to the publisher’s version if you intend to cite from the 
work. 
Publisher: Nature Publishing Group 
All outputs in CentAUR are protected by Intellectual Property Rights law, 
including copyright law. Copyright and IPR is retained by the creators or other 
copyright holders. Terms and conditions for use of this material are defined in 
the End User Agreement . 
www.reading.ac.uk/centaur 
CentAUR 
Central Archive at the University of Reading 
Reading’s research outputs online
Neurogenic responses mediated by vanilloid receptor-1 (TRPV1)
are blocked by the high anity antagonist, iodo-resiniferatoxin
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1 Stimulation of the vanilloid receptor-1 (TRPV1) results in the activation of nociceptive and
neurogenic inflammatory responses. Poor specificity and potency of TRPV1 antagonists has,
however, limited the clarification of the physiological role of TRPV1.
2 Recently, iodo-resiniferatoxin (I-RTX) has been reported to bind as a high anity antagonist at
the native and heterologously expressed rat TRPV1. Here we have studied the ability of I-RTX to
block a series of TRPV1 mediated nociceptive and neurogenic inflammatory responses in dierent
species (including transfected human TRPV1).
3 We have demonstrated that I-RTX inhibited capsaicin-induced mobilization of intracellular Ca2+
in rat trigeminal neurons (IC50 0.87 nM) and in HEK293 cells transfected with the human TRPV1
(IC50 0.071 nM).
4 Furthermore, I-RTX significantly inhibited both capsaicin-induced CGRP release from slices of
rat dorsal spinal cord (IC50 0.27 nM) and contraction of isolated guinea-pig and rat urinary bladder
(pKB of 10.68 and 9.63, respectively), whilst I-RTX failed to alter the response to high KCl or SP.
5 Finally, in vivo I-RTX significantly inhibited acetic acid-induced writhing in mice (ED50
0.42 mmol kg71) and plasma extravasation in mouse urinary bladder (ED50 0.41 mmol kg71).
6 In in vitro and in vivo TRPV1 activated responses I-RTX was *3 log units and *20 times more
potent than capsazepine, respectively. This high anity antagonist, I-RTX, may be an important
tool for future studies in pain and neurogenic inflammatory models.
British Journal of Pharmacology (2003) 138, 977 – 985. doi:10.1038/sj.bjp.0705110
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Abbreviations: HEK, human embryonic kidney; I-RTX, iodo-resiniferatoxin; RTX, resiniferatoxin; TRPV1, vanilloid receptor-1
Introduction
A subset of primary sensory neurons found within dorsal
root (DRG), trigeminal and vagal ganglia, which include
both C and Ad fibres, contain the neuropeptides, substance P
(SP), neurokinin A (NKA) and calcitonin gene-related
peptide (CGRP) (Holzer, 1991). These neuropeptides are
released from central and peripheral terminals of these
neurons upon activation of a recently cloned (Caterina et
al., 1997), non-selective cation channel that belongs to the
transient receptor potential (TRP) family of channels
(Gunthorpe et al., 2002). Because of the ability of this
channel to be gated by capsaicin, the pungent ingredient
found in chilli peppers, and by other molecules with a
vanilloid moiety (Szallasi & Blumberg, 1999) it has been
termed vanilloid receptor-1 (TRPV1) (Caterina et al., 1997).
An heterogeneous series of physical and chemical agents has
been shown to activate and/or potentiate the activity of
TRPV1. These agents include noxious heat (43 – 528C)
(Caterina et al., 1997), protons (pH 6-5) (Bevan & Geppetti,
1994; Tominaga et al., 1998), anandamide (Zygmunt et al.,
1999), 12-HPETE and other lipid derivatives (Hwang et al.,
2000) and ethanol (Trevisani et al., 2002). Two dierent
studies performed in TRPV1 null mice indicate that TRPV1
mediates thermal hyperalgesia (Caterina et al., 2000; Davis et
al., 2000). Recent findings that TRPV1 immunoreactivity is
higher in gastrointestinal tissues taken from patients with
ulcerative colitis and Crohn’s disease (Yiangou et al., 2001),
suggest that TRPV1 may play a role in the mechanism of
these inflammatory conditions. However, the role of TRPV1
in the pathophysiology of such diseases is still elusive, and
one of the reasons for these uncertainties is the absence of
high anity and selective TRPV1 antagonists.
Ruthenium red, a dye that exhibits properties of non-
competitive antagonism for the TRPV1 (Amann & Maggi,
1991), has a poorly defined mechanism of action and its
selectivity, if any, is restricted to a very narrow range of
concentrations (Szallasi & Blumberg, 1999). The search for a
selective TRPV1 blocker, and potential novel analgesic, led to
the discovery of capsazepine (Bevan et al., 1992; Dickenson &
Dray, 1991; Urban & Dray, 1991). Capsazepine was
characterized as a competitive TRPV1 antagonist but is
hindered by moderate potency (EC50 values ranging from 0.2
to 5 mM) (Acs et al., 1997; Bevan et al., 1992; Caterina et al.,
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1997; Liu & Simon, 1997; Szallasi et al., 1993; Wardle et al.,
1996). In addition, at the concentrations (*10 mM) often
required for antagonistic activity, capsazepine has shown
non-specific eects, including blockage of voltage-gated
calcium channels (Docherty et al., 1997) and nicotinic
receptors (Liu & Simon, 1997; Wardle et al., 1997).
The ultrapotent TRPV1 agonist, resiniferatoxin (RTX), a
toxin isolated from the cactus Euphorbia resinifera (Szallasi &
Blumberg, 1999) has been successfully used to label the
TRPV1 in radioreceptor binding assays by using its [3H] and
[125I] derivatives. Recently, it has been reported (Wahl et al.,
2001) that the iodinated form of resiniferatoxin (iodo-
resiniferatoxin (I-RTX): 6,7-Deepoxy-6,7-didehydro-5-deoxy-
21-dephenyl-21-(phenylmethyl)-daphnetoxin,20-(4-hydroxy-5-
iodo-3-methoxybenzeneacetate) inhibited the binding of [125I]-
RTX to rat spinal cord membranes and HEK293 cells
transfected with the rat TRPV1 with an anity much higher
than capsazepine (Ki, *5 nM and *5 mM, respectively).
Because I-RTX did not show any agonistic activity, blocked
capsaicin-induced currents in Xenopus leavis oocytes expres-
sing the rat TRPV1 (IC50 3.9 nM) and reduced the
nociceptive response induced by intrathecal capsaicin injec-
tion in mice, it was proposed that I-RTX behaves as a high
anity TRPV1 antagonist (Wahl et al., 2001).
A high anity and selective TRPV1 antagonist, in addition
to being a lead for developing novel analgesics, may be of
unprecedented value for discovering endogenous TRPV1
agonists and exploring the physiological role of TRPV1.
TRPV1 stimulation results in the activation of a series of
nociceptive and neurogenic inflammatory responses (Holzer,
1991; Szallasi & Blumberg, 1999; Szallasi & Di Marzo, 2000).
Thus, the present study was undertaken to define the ability
of I-RTX to inhibit ‘typical’ TRPV1 mediated responses in
dierent mammalian species. These responses include capsai-
cin-induced increases in intracellular Ca2+ ([Ca2+]i) in
cultured primary sensory neurones or HEK293 cells
transfected with the human TRPV1 (hTRPV1 HEK293),
release of CGRP and SP from slices of rat dorsal spinal cord,
contraction of isolated guinea-pig bronchus or urinary
bladder and of rat urinary bladder, neurogenic plasma
protein extravasation in the mouse urinary bladder and
acetic acid-induced writhing response in mice.
Methods
Animals and tissues
Male albino Dunkin-Hartley guinea-pigs (* 250 g), Sprague-
Dawley rats (*300 g) and Swiss mice (*30 g) were used
(Morini, Italy). All experiments complied with the national
guidelines and were approved by the regional ethics
committee.
Ca2+ fluorescence measurements in cultured rat
trigeminal ganglia and hTRPV1 HEK293 cells
Newborn rats (2 – 3 days old) were terminally anaesthetized
and decapitated. The trigeminal ganglia were removed and
rapidly placed in cold phosphate buered solution (PBS)
before being transferred to collagenase/dispase (1 mg ml71
dissolved in Ca2+-Mg2+-free PBS) for 35 min at 378C.
Enrichment of the fraction of nociceptive neurons was
obtained following the methods reported previously (Gilabert
& McNaughton, 1997). After the enzymatic treatment ganglia
were rinsed three times with Ca2+-Mg2+-free PBS and then
placed in 2 ml of cold DMEM supplemented with 10% foetal
bovine serum (FBS, heat inactivated), 2 mM L-glutamine,
100 u ml71 penicillin and 100 mg ml71 streptomycin. The
ganglia were then dissociated into single cells by several
passages through a series of syringe needles (23G down to
25G). Finally, the complex of medium and ganglia cells were
sieved through a 40 mm filter to remove debris and topped up
with 8 ml of DMEM medium and centrifuged (2006g for
5 min). The final cell pellet was re-suspended in DMEM
medium (supplemented with 100 ng ml71 mouse Nerve
Growth Factor (mouse-NGF-7S) and cytosine-b-D-arabino-
furanoside free base (ARA-C) 2.5 mM). Cells were plated on
poly-L-lysine (8.3 mM) and laminin (5 mM) coated 25 mm
glass cover slips and kept for 2 to 5 days at 378C in a
humidified incubator gassed with 5% CO2 and air. Cells were
fed on the second day (and subsequent alternate days) with
DMEM medium (with 1% FBS instead of 10% FBS). In
another set of experiments hTRPV1 HEK293 were also used.
Experiments were performed as previously reported in rat
DRG neurons (Tognetto et al., 2001). Briefly, plated neurons
and hTRPV1 HEK293 cells (2 to 5 days) were loaded with
Fura-2-AM-ester (3 mM) in Ca2+ buer solution of the
following composition (mM): CaCl2 1.4, KCl 5.4, MgSO4
0.4, NaCl 135, D-glucose 5, HEPES 10 with BSA 0.1%, at
pH 7.4, for 40 min at 378C, washed twice with the Ca2+
buer solution and transferred to a chamber on the stage of
Nikon eclipse TE300 microscope. The dye was excited at 340
and 380 nm to indicate relative [Ca2+]i changes by the F340/
F380 ratio recorded with a dynamic image analysis system
(Laboratory Automation 2.0, RCS, Florence, Italy). Capsai-
cin (0.1 mM), I-RTX (0.001 – 1 nM), capsazepine (0.01 –
10 mM) or their respective vehicles were added to the
chamber. A calibration curve using a buer containing
Fura-2-AM-ester and determinant concentrations of free
Ca2+ (Kudo et al., 1986) was used to convert the data
obtained from F340/F380 ratio to [Ca
2+]i (nM). Furthermore,
I-RTX (10 nM) did not aect the response produced by
ionomycin (5 mM) (data not shown).
CGRP-LI and SP-LI release from rat spinal cord
Rats were terminally anaesthetized and decapitated. The
dorsal spinal cord was prepared at 48C using a tissue slicer
(McIlwain Tissue Chopper, U.K.). Slices (*100 mg) were
placed in 2 ml chambers and superfused at 0.4 ml ml71 with
a Krebs solution of the following composition (mM) NaCl
119, NaHCO3 25, KH2PO4 1.2, MgSO4 1.5, CaCl2 2.5, KCl
4.7 and D-glucose 11. To the basic Krebs solution the
following agents were added: 0.1% bovine serum albumin
(BSA), 1 mM phosphoramidon and 1 mM captopril, and
maintained at 378C (gassed with 95% O2 and 5% CO2).
High KCl solution was prepared by changing isoosmotically
NaCl with KCl. After a 90 min stabilization period, 10 min
fractions were collected into acetic acid (final solution 2 N).
Two pre-stimuli samples were taken at 10 min intervals
followed by a third set of samples during stimulation. A final
post-stimulus 10 min sample was also collected. At the end of
the experiment tissues were blotted and weighed. Fractions
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were freeze-dried, re-constituted with assay buer, and
analysed by enzyme-immunoassays for CGRP and SP like
immunoreactivities (LI) (CGRP-LI and SP-LI, respectively)
according to the methods reported previously (Frobert et al.,
1999; Ricciardolo et al., 2000). The detection limits of the
assays were 5 pg ml71 for CGRP and 2 pg ml71 for SP. The
level of release of CGRP-LI and SP-LI were calculated by
subtracting the mean pre-stimulus value from those values
obtained during- and post-stimulation. The results are
expressed as fmol of peptide g71 tissue 20 min. The highest
concentration of capsaicin (10 mM), I-RTX (1 nM) and
capsazepine (10 mM) did not show any significant cross-
reactivity with CGRP and SP antisera.
Isolated tissues in organ baths
Animals were sacrificed by cervical dislocation and the
airways and urinary bladder of the guinea-pig, and urinary
bladder of the rat were removed. In the guinea-pig, rings
from main bronchi (approximately 2 mm in width) were
suspended with a resting tension of 1.5 g. In both the guinea-
pig and rat urinary bladders vertical halves were suspended
with a resting tension of 1 g. The tissues were bathed and
aerated (95% O2 and 5% CO2) with Krebs solution
(described above) which was maintained at 378C, and
contained phosphoramidon (1 mM) and captopril (1 mM) to
minimize peptide degradation. Tissues were allowed to
equilibrate for 60 min prior to the beginning and between
each set of experiments (washed every 5 min). In all
experiments the tissues were first contracted with carbachol
(CCh, 1 mM).
Cumulative concentration-response curves were performed
with capsaicin (0.1 nM– 100 mM) and SP (0.1 nM– 1 mM)
either in the presence of the TRPV1 antagonists, I-RTX
(0.01 – 1 mM in bronchi and 0.1 – 10 nM in urinary bladders)
and capsazepine (0.1 – 10 mM in all tissues) or their respective
vehicles. In a subset of experiments cumulative concentration-
response curves were also performed with resiniferatoxin
(0.1 nM– 1 mM).
Plasma extravasation
Swiss mice were anaesthetized with xylazine (100 mg kg71,
i.m.) and ketamine (50 mg kg71, i.m.). Evans Blue
(30 mg kg71) was injected into the femoral vein and 1 min
later the administration of capsaicin (1 mmol kg71, i.v.) was
performed. After five additional min animals were transcar-
dially perfused. Pre-treatments with I-RTX (0.1 –
0.5 mmol kg71, i.v.), capsazepine (0.5 – 10 mmol kg71, i.v.),
or their respective vehicles were given 20 and 15 min prior to
the injection of the dye, respectively. Urinary bladders were
removed, weighed and incubated in 1 ml of formamide for
24 h in the dark, at room temperature. The amount of
extravasated Evans Blue was measured spectrophotometri-
cally at 620 nm.
Writhing test
Swiss mice (*25 g) were intraperitoneally (i.p.) injected with
acetic acid (0.9%, 5 ml kg71) after pretreatment with I-RTX
(0.1 – 1 mmol kg71, i.p. 20 min prior to the stimulus),
capsazepine (1 – 10 mmol kg71, i.p. 60 min prior to the
stimulus) or their vehicles (0.01 – 0.1% DMSO and 0.01 –
0.1% ethanol, respectively).
Materials
Drugs and reagents were obtained from the indicated
companies: acetic acid, capsaicin, capsazepine, captopril,
ionomycin, laminin, phosphoramidon, poly-L-lysine, resini-
feratoxin, substance P (Sigma, Italy); iodo-resiniferatoxin
(Tocris, U.K.); mouse NGF-7S and collagenase/dispase
(Roche Diagnostics, Italy); Dulbecco’s Modified Eagle’s
medium (DMEM), foetal bovine serum (FBS) heat inacti-
vated, L-glutamine (200 mM), penicillin/streptomycin
(10,000 IU ml71 – 10,000 UG ml71), Ca2+-Mg2+-free phos-
phate buered solution (PBS) (Gibco, Italy); Fura-2-AM-
ester (Societa’ Italiana Chimici, Italy). SLIGKV-NH2 was
synthesized at the Laboratory of Pharmaceutical Sciences of
the University of Ferrara. The stock concentrations of
capsaicin (10 mM), capsazepine (10 mM) and resiniferatoxin
(10 mM) were prepared in 100% ethanol. Fura-2-AM-ester
and ionomycin were dissolved in 100% DMSO. All other
drugs were dissolved in distilled water. The appropriate
dilutions were then made in Krebs buer solution.
Statistical analysis
The arithmetic mean and standard error of the mean were
calculated throughout. Contractile responses are expressed as
a percentage (%) of the response to CCh (1 mM). The
concentration/dose of an agonist or antagonist that produced
50% of the maximal eect (EC50, IC50 and ED50) were
obtained with an iterative curve fitting package (GraphPad
Prism Software, San Diego, CA, U.S.A.; Origin Software,
Microcal Software, Northampton, MA, U.S.A.). Values for
pKB, as a measure of the antagonist anity were calculated
according to Kenakin (1993). The pKB value was calculated
for each tissue, with the final value given as mean+s.e.mean.
Statistical analysis was performed by means of the Student’s
t-test or analysis of variance (ANOVA) and the Dunnett’s
test when required. If P50.05 the results were considered
significant.
Results
Ca2+ fluorescence measurements in cultured rat
trigeminal ganglia and hTRPV1 HEK293 cells
Capsaicin (0.1 mM) caused an increase in [Ca2+]i in the vast
majority (495%) of rat trigeminal neuronal cells (64+9% of
ionomycin, n=85), that therefore were identified as TRPV1
expressing neurons. The threshold concentration of I-RTX
that produced an inhibitory eect was 0.1 nM and complete
inhibition of the response to capsaicin was obtained with
10 nM I-RTX. IC50 of I-RTX to inhibit capsaicin-evoked
[Ca2+]i mobilization was 0.87 nM (Figures 1 and 2 and Table
1). For capsazepine (IC50, 2344 nM) threshold and blocking
concentrations were 1 mM and 100 mM, respectively (Figures 1
and 2 and Table 1). Mobilization of [Ca2+]i evoked by 5 mM
KCl (94+13% of ionomycin, n=44) was not aected by I-
RTX (1 mM) (90+4% of ionomycin, n=38).
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Practically all the hTRPV1 HEK293 cells responded to
0.1 mM capsaicin evoking a remarkable increase in [Ca2+]i
(54+3% of ionomycin, n=57). The threshold concentration
of I-RTX to show an inhibitory eect was 0.03 nM and
complete inhibition of the response to capsaicin was obtained
with 3 nM I-RTX. IC50 of I-RTX to inhibit capsaicin-evoked
[Ca2+]i mobilization was 0.071 nM (Figure 1 and Table 1).
For capsazepine (IC50 was 912 nM) the threshold and
blocking concentrations were 1 mM and 10 mM, respectively
(Table 1). Mobilization of [Ca2+]i evoked by the proteinase
activated receptor-2 (PAR2) agonist, SLIGKV-NH2 (10 mM)
(87+6% of ionomycin, n=98) was not aected by I-RTX
(1 mM) (97+12% of ionomycin, n=60). I-RTX (1 mM), in
both rat trigeminal neurons and hTRPV1 HEK293 cells did
not cause any visible increase in [Ca2+]i.
CGRP-LI and SP-LI release from rat spinal cord
Next we examined the eect of TRPV1 antagonists on
capsaicin-induced release of CGRP-LI and SP-LI from slices
of rat spinal cord. Capsaicin (0.1 mM) increased CGRP-LI
and SP-LI outflow (488+90 fmol g71 20 min, n=5; and
31.5+3.5 fmol g71 20 min, n=5, respectively). Exposure of
spinal cord slices to either I-RTX (1 nM) or capsazepine
Figure 1 Typical tracings and microscopic images showing the
inhibitory eect of iodo-resiniferatoxin (I-RTX, 0.1 nM) or capsaze-
pine (CPZ, 0.1 nM) on capsaicin (0.1 mM) induced Ca2+ mobilization
in rat trigeminal neurons (A, C) and HEK293 cells transfected with
the human TRPV1 (hTRPV1 HEK293; B, C).
Figure 2 The inhibitory eect of iodo-resiniferatoxin (I-RTX, filled
circles), capsazepine (CPZ, open circles) on capsaicin (0.1 mM)
-induced increases in cytoplasmic Ca2+ ion concentration in rat
trigeminal neurons (A) and HEK293 cells transfected with the human
TRPV1 (hTRPV1 HEK293; B). Each entry is the mean+s.e.mean of
at least 80 cells; *P50.05.
Table 1 Anities of capsazepine and iodo-resiniferatoxin
for the TRPV1 in in vitro and in vivo in a number of
responses activated by capsaicin
Iodo-
Capsazepine Resiniferatoxin
In vitro
Guinea-pig pKB pKB
Urinary bladder 6.56+0.20 10.68+0.24
Bronchus 6.29+0.31 7.26+0.40
Rat pKB pKB
Urinary bladder 6.22+0.40 9.63+0.30
Rat IC50 (nM) IC50 (nM)
TG neurons (Ca2+) 2344+53.9 0.871+0.009
CGRP release 3802+0.04 0.269+0.06
(dorsal spinal cord)
Human IC50 (nM) IC50 (nM)
TRPV1 HEK cells 912.0+10.5 0.071+0.001
In vivo
Mouse ED50 ED50
(mmol kg71) (mmol kg71)
Plasma extravasation 9.03+1.02 0.41+0.08
Writhing (acetic acid) 7.90+1.13 0.42+0.05
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(10 mM) did not produce any significant increase in CGRP-LI
or SP-LI (data not shown) outflow. Pre-treatment with I-
RTX (0.01 – 1 nM) and capsazepine (1 – 10 mM, Figure 3)
reduced the capsaicin-induced increase in CGRP-LI outflow
in a concentration-dependent manner, with IC50 that were
0.269 nM and 3802 nM, respectively (Table 1). I-RTX (1 mM)
did not alter the release induced by a high KCl (80 mM)
concentration (Figure 3).
Contractile responses in isolated guinea-pig bronchus and
urinary bladder, and rat urinary bladder
Capsaicin evoked a robust concentration-related contraction
of guinea-pig isolated bronchi and urinary bladder, and rat
urinary bladder. Threshold concentration of capsaicin to
cause a visible contractile eect was 1 nM in all tissues tested,
and maximum response (% of CCh 1 mM, Emax) obtained
with 1 mM of capsaicin was 107+9% (n=20) in guinea-pig
bronchus, 58+12% (n=15) in guinea-pig urinary bladder
and 39+14% (n=12) in rat urinary bladder. Exposure to I-
RTX (1 mM) did neither aect the baseline tension in all the
three tissues examined nor change the response to CCh 1 mM
(data not shown). I-RTX (1 nM – 1 mM) caused a concentra-
tion-dependent and surmountable antagonism of capsaicin-
induced contraction in all the tissues tested. Schild plot
analysis of the results revealed pKB values in the guinea-pig
bronchi and urinary bladder of 7.26+0.40 (n=12, Figure 4)
and 10.68+0.24 (n=10, Figure 5) respectively, and in rat
urinary bladder of 9.63+0.30 (n=12, Figure 6) (Table 1). A
similar study was performed with capsazepine (0.1 – 10 mM)
against capsaicin-induced contraction: pKB values in the
guinea-pig bronchus and urinary bladder were 6.29+0.31
(n=8, Figure 4) and 6.56+0.20 (n=8, Figure 5) respectively,
and in the rat urinary bladder was 6.22+0.40 (n=9, Figure
6) (Table 1). I-RTX (0.1 nM– 1 mM) did not aect the
cumulative concentration response curve produced by SP in
isolated guinea-pig bronchi (Figure 4) and urinary bladder
(Figure 5), and rat urinary bladder (Figure 6).
I-RTX had no eect on baseline tone at any of the
concentrations tested (1 nM, 10 nM, 100 nM and 1 mM) and in
any of the isolated tissues (data not shown). In contrast,
RTX (0.1 – 100 nM) caused a robust contractile response
starting at 0.3 nM producing a maximum contraction similar
to that of capsaicin (data not shown).
Plasma protein extravasation in mouse urinary bladder
Intravenous (i.v.) injection of capsaicin (1 mmol kg71)
induced a significant increase in plasma extravasation in
mouse urinary bladder (11.2+1.3 ng EB/g of tissue, n=6) as
compared to the extravasation produced by the vehicle of
capsaicin (4.1+0.7 ng EB/g of tissue, n=6, P50.01).
Pretreatment with I-RTX (0.1 – 0.5 mmol kg71, i.v.) caused a
dose-related inhibition (ED50 0.41+0.08 mmol kg71, Figure 7
and Table 1). Capsazepine (0.5 – 10 mmol kg71, i.v.) pretreat-
ment also inhibited capsaicin-induced plasma extravasation in
the urinary bladder with an estimated ED50 of
9.03+1.02 mmol kg71 (Figure 7 and Table 1). At the
maximum dose used, I-RTX (0.5 mmol kg71, i.v.) alone
neither produced any measurable increase in PE (data not
shown) nor aected SP induced plasma extravasation in the
mouse urinary bladder (Figure 7).
Writhing in mice
Intraperitoneal injections of acetic acid (0.9%, 5 ml kg71)
evoked a significant increase in stereotypical writhing
Figure 3 The inhibitory eect of iodo-resiniferatoxin (I-RTX,
closed bars), capsazepine (CPZ, hatched bars) or the combination
of their respective vehicles (empty bar) on the release of calcitonin
gene-related peptide-like immunoreactivity (CGRP-LI) induced by
capsaicin (0.1 mM) or KCl (80 mM) from slices of rat dorsal spinal
cord. Each entry is the mean+s.e.mean of at least five experiments;
*P50.05.
Figure 4 The eect of iodo-resiniferatoxin (I-RTX), capsazepine
(CPZ) or their respective vehicles (empty circles) on the contraction
produced by increasing concentrations of capsaicin (A, B) or
substance P (C) (both given in a cumulative manner) in isolated
guinea-pig bronchial rings. Each entry is the mean+s.e.mean of at
least six experiments.
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responses over 20 min in mice. These writhing episodes were
significantly reduced by pre-treatment with I-RTX (0.1 –
1 mmol kg71, i.p.) in a dose-related manner (ED50:
0.42+0.05 mmol kg71, Figure 8). Capsazepine (1 –
10 mmol kg71, i.p.) also inhibited the acetic acid induced
writhing responses in mice with an ED50 of
7.90+1.13 mmol kg71 (Figure 8). I-RTX (1 mmol kg71, i.p.)
caused in a few instances (two out of six mice tested) a few
writhing responses (510/20 min).
Discussion
In the present study, we have investigated the ability of I-
RTX to inhibit ‘typical’ neurogenic inflammatory and
nociceptive responses produced by activation of TRPV1 in
experimental preparations from dierent mammalian species.
The main finding of this study is that I-RTX is a highly
potent TRPV1 antagonist in all the paradigms and species
examined, with the exception of the guinea-pig bronchus.
First, we examined the ability of I-RTX to reduce the
capsaicin-induced increase in [Ca2+]i in cultured trigeminal
neurons. In this preparation IC50 value of I-RTX was in the
subnanomolar range, thus showing that I-RTX was about
three log units more potent than capsazepine. These data are
in complete agreement with the study reported by Wahl et al.
(2001) where they estimated that the Ki of I-RTX for
displacement of [125I]-RTX binding from membranes of
native (rat spinal cord) or recombinant (rat TRPV1
HEK293 cells) TRPV1 was approximately 1000 fold lower
than that of capsazepine. In the present study I-RTX showed
selectivity because at the highest concentration used it did not
aect the increase in [Ca2+]i produced by a high K
+ medium.
Because KCl-induced [Ca2+]i mobilization in sensory neurons
is mediated by the influx of extracellular Ca2+ mainly
through N and L type voltage sensitive Ca2+ channels, these
findings indicate that I-RTX does not inhibit these type of
channels. Furthermore, I-RTX showed a very high anity
for the human TRPV1 expressed in HEK293 cells, where I-
RTX inhibited the capsaicin-induced increase in [Ca2+]i with
an IC50 of 0.071 nM confirming a similar previous observa-
tion (McDonnell et al., 2002). The inhibitory response of I-
RTX was more than four log units lower than that of
capsazepine and 10 fold lower than that observed for I-RTX
at the rat TRPV1 which is consistent with recent finding that
antagonism at TRPV1, in this case by capsazepine, is greater
in cells expressing human TRPV1 as compared to the rat
(McIntyre et al., 2001; Wahl et al., 2001). HEK293 cells
express constitutively the proteinase activated receptor-2
(PAR2) (Hollenberg et al., 1997). The observation that I-
RTX did not aect PAR2 agonist-induced increases in
[Ca2+]i indicates a degree of selectivity for the human
TRPV1.
Increases in [Ca2+]i produced by TRPV1 activation result
in a series of intracellular events that lead to secretion of
neuropeptides from peripheral and central endings of primary
Figure 5 The eect of iodo-resiniferatoxin (I-RTX), capsazepine
(CPZ) or their respective vehicles (empty circles) on the contraction
produced by increasing concentrations of capsaicin (A, B) or
substance P (C) (given in a cumulative manner) in isolated strips of
guinea-pig urinary bladder. Each entry is the mean+s.e.mean of at
least six experiments.
Figure 6 The eect of iodo-resiniferatoxin (I-RTX), capsazepine
(CPZ) or their respective vehicles (empty circles) on the contraction
produced by increasing concentrations of capsaicin (A, B) or
substance P (C) (given in a cumulative manner) in isolated strips of
rat urinary bladder. Each entry is the mean+s.e.mean of at least six
experiments.
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sensory neurons. SP and CGRP release from central
terminals of primary aerents is considered to be a major
function of nociceptors because it has been associated with
pain transmission (Otsuka & Yanagisawa, 1990). In this
important assay I-RTX also proved to be a high anity
antagonist of the rat TRPV1, being more than 1000 fold
more potent than capsazepine. Again, the observation that
1 mM I-RTX did not aect the ability of high K+ ion
concentrations to release CGRP/SP indicates selectivity for
TRPV1 over voltage-gated mechanisms.
Release of neuropeptides from peripheral terminals of
primary sensory neurons that ensues from TRPV1 activation
causes a series of responses collectively referred to as
‘neurogenic inflammation’ (Geppetti & Holzer, 1996). In the
airways and urinary bladder neurogenic inflammatory
responses include contraction of the bronchial and urinary
smooth muscle and extravasation of plasma proteins in
postcapillary venules. I-RTX was extremely potent in
inhibiting capsaicin-induced contractions of the guinea-pig
and rat urinary bladder. As in other assays, the pKB of I-
RTX was in both these cases more than three log units higher
than that of capsazepine. At variance with all these
observations, I-RTX potency to reduce capsaicin-induced
contractions of guinea-pig bronchi was much lower (*100x)
than that found in all the other preparations studied, and
only slightly higher than that of capsazepine. This finding is
consistent with previous reports that showed a low anity
constant of RTX (either iodinated or not) in binding assays
using guinea-pig bronchial tissues (Szallasi et al., 1993). The
observation that in the guinea-pig urinary bladder I-RTX
shows a potency similar to that observed at the rat and
human TRPV1, excludes that I-RTX has a low anity for
the guinea-pig TRPV1, but rather suggests that some hitherto
unknown mechanism(s), specific for the guinea-pig bronchus
is responsible for the low capability of RTX (Szallasi et al.,
1993) and I-RTX to bind and (I-RTX) inhibit the TRPV1 in
this tissue.
One possible explanation for the remarkable potency of I-
RTX to inhibit the TRPV1 in dierent mammal species is
that this molecule retains some agonistic activity from the
parent drug, RTX, that causes desensitization of TRPV1 and
of downstream mechanisms resulting from TRPV1 activation
(Szallasi et al., 1993). However, the absolute absence of any
visible agonist eect of low and even high I-RTX concentra-
tions, in all the preparations tested, suggests that I-RTX does
not act via first activating and then desensitizing the TRPV1/
sensory nerve terminal, but most likely by its ability to
antagonize the channel.
The low potency and poor selectivity for TRPV1 of
ruthenium red and capsazepine has limited their use,
particularly in in vivo studies. The present investigation,
using a classical TRPV1 mediated in vivo response in the
form of the capsaicin-induced plasma extravasation in the
urinary bladder, shows that I-RTX is much more potent than
capsazepine. The lack of eect of high doses of I-RTX upon
SP-induced plasma extravasation indicates that TRPV1 and
I-RTX act upstream of the release of tachykinins which
stimulates NK1 receptors on endothelial cells of the
postcapillary venule and it provides further support for the
Figure 7 The eect of iodo-resiniferatoxin (I-RTX), capsazepine
(CPZ) or the combination of their respective vehicles (black bars) on
the Evans blue extravasation induced by the intravenous injection of
capsaicin (Caps) or substance P (SP) in the mouse urinary bladder.
Each entry is the mean+s.e.mean of at least six experiments;
*P50.05.
Figure 8 The inhibitory eect of iodo-resiniferatoxin (I-RTX),
capsazepine (CPZ) or the combination of their respective vehicles
(empty bar) on the number of writhing responses produced by
intraperitoneal administration of acetic acid in mice. Each entry is
the mean+s.e.mean of at least seven experiments; *P50.05.
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selectivity of I-RTX both in vivo as well as in vitro. An
important point for the use of I-RTX for pathophysiological
investigations is to demonstrate that this compound may
block responses induced by endogenous stimulants of
TRPV1. Acidic media have been proposed to be putative
endogenous agonists of TRPV1 (Bevan & Geppetti, 1994)
and the cloning of the rat TRPV1 has confirmed that protons
stimulate this receptor (Tominaga et al., 1998). A recent
study, showing that capsazepine inhibits the acetic acid
induced writhing behaviour in mice, suggested that this
complex nociceptive response involves an aerent arm in
which the TRPV1 has a role (Ikeda et al., 2001). We found
that I-RTX was about 20 fold more potent than capsazepine
in reducing the acetic acid-induced writhing, which has two
implications: firstly, it confirms the data obtained using
capsazepine using an additional antagonist, and secondly,
that I-RTX may be used to test the ability of putative
endogenous agonists to stimulate nociceptive responses
activated by the TRPV1.
In conclusion the present investigation confirms the early
observation (Wahl et al., 2001) that I-RTX is a potent
antagonist at the rat TRPV1. The study, for the first time
shows that I-RTX exhibits high anity for the TRPV1 in
additional mammal species including the guinea-pig and
human TRPV1. The fact that I-RTX at subnanomolar
concentrations and with high selectivity blocks TRPV1-
mediated responses indicates that this molecule may be an
invaluable tool for the restless search of the physiological
role(s) and of the putative endogenous pain-producing
agonist of TRPV1.
This work has been supported by grants from MURST (Cofin
2000), ARCA (Padua) and Consorzio Ferrara Ricerche, Italy.
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